Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 13/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.36 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6326197 | 0.88 | RORC (0.43) | — | |
| SCHEMBL6333754 | 0.87 | P2RX7 (0.41) | POLBL3MBTL1P2RX7HTR2ACCR3 | |
| SCHEMBL6326138 | 0.86 | HTR2A (0.38) | P2RX7HTR2A | |
| SCHEMBL6326076 | 0.86 | P2RX7 (0.36) | P2RX7HTR2ACCR3 | |
| SCHEMBL6330372 | 0.84 | TDP1 (0.37) | POLBALDH1A1P2RX7 | |
| SCHEMBL6326075 | 0.83 | HTR2A (0.38) | P2RX7HTR2A | |
| SCHEMBL6326051 | 0.81 | RORC (0.42) | — | |
| SCHEMBL6336600 | 0.79 | P2RX7 (0.40) | P2RX7HTR2ACCR3 | |
| SCHEMBL6330799 | 0.78 | P2RX7 (0.39) | P2RX7HTR2ACCR3 | |
| SCHEMBL6335084 | 0.78 | NPY2R (0.40) | P2RX7HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO. LTD. (JP) | 2005-04-21 | — | — | US | claimed |
| EP-1447401-A1 | PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-08-18 | — | — | EP | claimed |
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO. LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1447401-A1 | PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | MAPKAP1, MAPK1, MAPK8 | POLB 1872/4885L3MBTL1 2754/4885ALDH1A1 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.